Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study for CLL

Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study for CLL

Shots:

  • The P-III CLL14 Study involves assessing of Venclexta/Venclyxto + Gazyva/Gazyvaro vs Gazyva/Gazyvaro + chlorambucil in 432 patients with previously untreated CLL
  • P-III CLL14 Study results: ORR (84.7% vs 71.3%); CR (49.5% vs 23.1%); patients receiving Venclexta/Venclyxto lived longer; disease progression @2yrs. (88.2% vs 64.1%); no new safety signals observed
  • Venclexta/Venclyxto is a drug targeted for binding & inhibiting BCL-2 protein, further leads to apoptosis and has received 5 times FDA’s BT designation in combination or monothx with approval in 50+ countries. Roche and AbbVie collaborated to develop Venclexta/Venclyxto

CI Comments/ Implications:

  • The positive results from the CLL14 trial demonstrates the potential of venetoclax as a treatment with a fixed duration for patients with CLL and can be utilized as the basis to expand into 1L treatment
  • Venclexta/Venclyxto is being evaluated in several types of blood cancer, including AML & MM, though MM trials have been put on hold by FDA after death of patients

Click here to­ read full press release/ article | Ref: Roche| Image: Behance

administrator